Background-Socioeconomic deprivation is associated with increased heart failure (HF) incidence, hospitalization rates, and mortality. However, whether the delivery of survival-enhancing medical therapy is equitable remains uncertain. We examined secular trends in the uptake of key medical therapies (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, ␤-blockers, spironolactone) stratified by socioeconomic circumstances in patients with HF. Secondary analyses examined trends in HF incidence, prevalence, and survival. Methods and Results-This study was a cross-sectional observational analysis of nationally representative primary care data from England. Treatments for patients with HF in 1999 and 2007 (nϭ13 330) were extracted from the General Practice Research Database. Socioeconomic circumstances were defined with the Index of Multiple Deprivation 2007, a weighted composite of 7 area-level deprivation domains. Treatment uptake estimates were age standardized. The incidence and prevalence of HF decreased year to year. Although clear socioeconomic gradients in both the incidence and prevalence of HF were apparent, the absolute difference between most and least deprived reduced over time. Uptake of therapies improved over time in both men and women. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker uptake increased from 46% to 64%, ␤-blocker uptake from 12% to 41%, and spironolactone uptake from 3% to 20%. Modest age and sex inequalities were apparent. However, no consistent socioeconomic gradients were observed in either treatment or case fatality. Conclusions-Socioeconomic gradients in the incidence and prevalence of HF are reducing. Treatment is generally equitable and independent of socioeconomic circumstances. Most important, no significant inequality in outcomes was apparent. Future strategies should continue to address inequalities in the underlying causes of HF and to increase overall treatment levels further. (Circulation. 2012;126:1050-1057.)
S
ocioeconomic deprivation is associated with increased incidence and rates of hospitalization for heart failure (HF). 1 However, the relationship with mortality is less robust, being modest, 2, 3 restricted to specific subgroups, 4 or nonsignificant. 5 Even greater uncertainty surrounds the impact of socioeconomic circumstances on the actual treatment of HF patients. 2,6 -9 Previous reports have been limited in number, size of population, 7-9 range of treatments examined, 2, 6, 8 contemporariness, 2,7-9 and trend analyses over time. The paucity of evidence reflects the limited ability of many international healthcare systems to link medication and socioeconomic information.
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Three key medical therapies improve survival in patients with HF: angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), ␤-blockers, and aldosterone antagonists (mainly spironolactone). Studies in Scotland and the Netherlands examining all 3 therapies found little difference in prescribing patterns by deprivation categories. 7, 9 However, both examined prescribing more than a decade ago. A more recent study observed underuse of ␤-blockers among patients living in the most deprived areas of the United Kingdom. 6 The extent to which any healthcare system in the world is delivering equitable HF care is thus uncertain.
Access to and use of National Health Service care are universal in the United Kingdom. Treatment of HF should therefore be equitable, should be based solely on clinical need, and should be independent of ability to pay, age, sex, or other social factors. We therefore examined secular trends in the incidence, prevalence, treatment, and survival of commu-nity patients with HF since 1999 using nationally representative data stratified by socioeconomic quintiles.
Methods

Socioeconomic Circumstances
Socioeconomic circumstances were defined with the Index of Multiple Deprivation 2007 (IMD). 10 This is a composite measure of relative deprivation at a small area level (called lower super output areas) covering an average population of 1500 people. The overall index aggregates 38 indicators covering 7 dimensions of deprivation weighted as follows: income (22.5%), employment (22.5%), health and disability (13.5%), education, skills and training (13.5%), barriers to housing and services (9.3%), crime (9.3%), and living environment (9.3%). Deprivation indexes predating IMD such as the Carstairs Index and Townsend Index were compiled at the geographical level of electoral wards based solely on census data. In contrast, the IMD is more contemporary, combining census information with regularly updated administrative data during the intercensal period. These additional data include returns to government departments (Work and Pensions; Her Majesty's Revenue and Customs; Children, Schools and Families; Communities and Local Government; Office for National Statistics) and nongovernmental agencies (National Asylum Support Service, Prescribing Pricing Authority, Crime and Disorder Reduction Partnership, Higher Education Statistics Agency).
The IMD is better suited to measuring change over time because the lower super output area boundaries remain fixed over time (unlike electoral wards). The smaller mean population (typically 1500 as opposed to 6000 people in electoral wards) improves the population homogeneity and reduces grouping of residents with differing levels of deprivation. 11 The 32 482 lower super output areas in England were ranked in ascending order of deprivation score and grouped in equal fifths, with quintiles 1 and 5 representing the most affluent and most deprived areas, respectively. The postcode address of individual patients was linked to the lower super output area and hence the corresponding deprivation quintile. Although lack of deprivation does not necessarily equate to affluence, to assist readability, we refer to quintile 1 as most affluent and quintile 5 as most deprived.
Patient Groups
Adults with HF (nϭ13 330 in 2007) Ն25 years of age were identified with the UK General Practice Research Database (GPRD). The GPRD is the world's largest longitudinal database of anonymized primary care records linked to morbidity and prescribing information. 12 Several studies have confirmed the validity of diagnostic and prescription data in the GPRD. [12] [13] [14] [15] The database includes Ϸ3.2 million active patients, representing 6% of the UK population. Of these, 1.6 million (51%) are registered in practices with postcode linkage allowing classification of socioeconomic circumstances. The age/sex distribution and crude death rate were compared in linked and unlinked practices against the national Census population in 2001 (the gold standard) and against midyear population estimates for 2007 from the Office for National Statistics. Relative to the general population, the sex split marginally favored men in the GPRD and age-standardized mortality was slightly lower in the GPRD overall. However, no significant differences were observed between linked and unlinked samples.
Prevalent HF cases were defined as all living patients assigned a physician diagnosis of HF (with the use of the Read or OXMIS codes) before the first day of the active calendar year. Incident cases included all newly assigned diagnoses within the year. Code lists were identified from previous literature and consultations with clinicians (Table I in the online-only Data Supplement). All GPRD data have multicenter research ethics committee approval for observational studies.
Treatment Uptake and Survival
Drug treatment in the calendar year of interest was identified with Multilex drug codes, which can be mapped to the British National Formulary classification. Uptake therefore relates to prescriptions issued and recorded by general practitioners, not to prescriptions dispensed. One-year case fatality rates among the population with HF (ever having had the condition at the beginning of each calendar year) were calculated as the number of deaths in the calendar year divided by the sum of person-time. The pooled case fatality rate for each deprivation quintile was calculated with the use of deaths and person-time over the entire study period.
Statistical Analysis
Rates were calculated by repeated cross-sectional analysis of data from each individual year. All rates (treatment uptake, incidence, prevalence, case fatality) were directly standardized to the European Standard Population using 10-year age bands to Ն85 years of age. Standard errors for medical use were computed on aggregate data by use of the Poisson approximation. 16 Rate ratios (RRs) and associated 95% confidence intervals (CIs) were calculated by comparing directly age-standardized rates from the most and least deprived quintiles.
Annual changes in incidence, prevalence, and case fatality rates were assessed by fitting a linear regression trend line to the logarithmic annual values of the age-standardized rates. The average annual rate of change was obtained by [exponential(b)Ϫ1], where b represents the ordinary least squares estimate of the slope. The 95% CIs were calculated from the standard errors of the trend coefficient produced by the regression model. Analyses were run on aggregate data with Stata Version 11.1.
Results
To frame results precisely and to assess the impact of changing demographics, the age-sex constitution of the HF and general population was examined in the baseline and final years (the Table) . Congruent with the short time span, the age-sex structure of the overall population was stable. The proportion of patients with HF who were elderly (Ն75 years of age) was also unchanged (68.5% in 1999 versus 68.3% in 2007). Over the 8 years, the sex ratio altered slightly, shifting toward a greater proportion of men in 2007.
Epidemiology: Overall Rates
Baseline and subsequent trends in the overall incidence, prevalence, and case fatality rates for HF are presented in Figure 1 and Table II in the online-only Data Supplement. Both the incidence and prevalence declined over time ( Figure  1 and Table II in the online-only Data Supplement). From 1999 to 2007, the overall incidence reduced from 200 per 100 000 per to 60 per 100 000 (average annual decline, 14 per 100 000) and overall prevalence from 1.08% to 0.83% (average annual decline, 0.04%). Over the same time period, 1-year mortality was unchanged (5.2%).
Epidemiology: Socioeconomic Inequality
Absolute inequalities were reduced between 1999 and 2007.
Comparing most and least deprived quintiles showed that incidence rates declined by 170 per 100 000 versus 130 per 100 000 and prevalence by 0.40% versus 0.29%, respectively. Accordingly, the absolute difference in incidence between the most and least deprived narrowed from 100 per 100 000 to 60 per 100 000 and in prevalence from 0.63% to 0.52%. However, relative inequalities widened slightly, with the corresponding RRs for incidence increasing from 1.62 (95% CI, 1.39 -1.88) to 2.33 (95% CI, 1.83-2.96) and for prevalence from 1.75 (95% CI, 1.64 -1.87) to 1.95 (95% CI, 1.82-2.09).
No consistent socioeconomic gradients were observed in case fatality rates ( Figure 1 ). RR estimates fluctuated from year to year, variably favoring most or least deprived, often with wide CIs. However, aggregating data across the 8-year period revealed no significant inequality in survival (RR, 1.24; 95% CI, 0.82-1.89).
Treatment: Overall Rates
Treatment with ACEI/ARB was well established in 1999 (46%). However, uptake improved further to 64% in 2007, an increase in relative terms of 37% (RR 1.37; 95% CI, 1.18 -1.60). ␤-Blockers and spironolactone were rarely prescribed in 1999, but both increased markedly in subsequent years ( Figure 2 and Table III 
Treatment: Socioeconomic Inequality
Overall, when men and women of all ages were combined, no significant socioeconomic gradients were apparent for any therapy ( Figure 2) . In a comparison of the most affluent and most deprived quintiles in 2007, the respective treatment levels were 60% versus 65% for ACEI/ARB (RR, 1.09; 95% CI, 0.84 -1.41), 40% versus 39% for ␤-blockers (RR, 0.97; 95% CI, 0.67-1.41), 17% versus 21% for spironolactone (RR, 1.21; 95% CI, 0.73-2.03), and 14% versus 16% for digoxin (RR, 1.15; 95% CI, 0.67-1.96; Table III in the online-only Data Supplement).
Socioeconomic differences in prescribing were examined separately for men and women in young (Ͻ55 years of age), middle-aged (55-74 years of age), and elderly (Ն75 years of age) patients. Again, no consistent gradients were observed for any individual treatment (Figure 3) . In those Ͻ55 years of age, some variability in point estimates for individual deprivation quintiles was apparent, a consequence of the low prevalence of HF at younger ages. However, any minor gradients were inconsistent between different therapies and failed to achieve statistical significance.
Discussion
Significant socioeconomic inequalities in the occurrence of HF persist. However, the UK National Health Service is delivering equitable care to community patients independently of socioeconomic circumstances.
Epidemiology: Overall Rates
The steady decline in HF incidence is consistent with recent studies from Scotland, 3 Sweden, 17 Australia, 18 New Zealand, 19 Canada, 20 and the United States. 21 Although the magnitude of decline in England exceeds these studies, our analysis is more contemporary and involves community as opposed to hospitalized patients. The prevalence pool is determined by inflows (incidence) and outflows (mortality). The slower decline in prevalence is thus congruent with the lower case fatality rate at the population level. Nevertheless, the extent of decline in incidence is surprising, and shifts in diagnostic or coding practices must be acknowledged as potential confounders.
Although numerous studies have defined the prognosis of patients with HF, most concentrated on hospitalized patients. Survival remains poor, with typical 1-year mortality of Ϸ30% and median survival of 2 years. 3, 20, 22 A single study has reported outcomes separately across the full spectrum of care: outpatient, emergency department, and hospital. 20 Although 1-year mortality for hospitalized patients was high (30%), mortality for those attending the general outpatient clinic was much lower (6.6%) and similar to our own. A recent randomized controlled trial of pharmacist intervention in UK primary care confirmed this lower community mortality (death rate, 7 per 100 patient-years). 23 
Epidemiology: Socioeconomic Inequality
This study is the first to disaggregate trends according to socioeconomic circumstances. Although gradients were apparent, the frequency of HF has declined more in the most deprived and reduced the gap between the deprived and affluent. As is often the case, narrowing in absolute terms magnified relative inequalities. The equity of the latter remains a contentious issue but should not overshadow the absolute improvements.
HF represents the end point of numerous pathophysiological processes. The potential causes of inequality are accordingly complex. Precursors of HF, including hypertension, diabetes mellitus, and coronary disease, are more common in deprived individuals. Rates of treatment, compliance, and adherence to therapy may influence outcomes. Furthermore, deprivation is associated with delayed presentation of myocardial infarction 24 and lower levels of secondary prevention 25 and revascularization. 26 The likelihood, extent, and progression of myocardial damage (and consequently HF) are therefore increased. The wider determinants of health may also adversely influence events culminating in HF 27 : education, health literacy, social support, access to health care, transportation, employment, environmental conditions, diet, smoking, and other risk factors.
To the best of our knowledge, only 5 studies have examined socioeconomic circumstances and survival in patients with HF, all after hospitalization but each using different measures of deprivation. [2] [3] [4] [5] 28 The increased 1-year case fatality associated with deprivation was typically modest (RR, 1.10 [95% CI, 1.02-1.19] 2 and RR, 1.11 [95% CI, 1.07-1.16] 3 ), restricted to those with a high comorbidity burden, 4 or nonsignificant. 5 Our community-based analysis suggests that socioeconomic factors have limited impact in stable patients. A number of explanations are plausible. Predictors of all-cause mortality that are independent of socioeconomic status may assume greater relative importance in stable patients. However, most leading causes of death exhibit some degree of social stratification. Alternatively, the results may reflect the equitable delivery of medical therapy and expansion of nurse-led community HF services reaching those with greatest need.
Treatment: Overall Rates
In just the 8 years between 1999 and 2007, uptake of ACEI/ARB increased from 46% to 64%, ␤-blocker uptake from 12% to 41%, and spironolactone uptake from 3% to 20%. Analysis from the UK Doctors Independent Network (DIN-LINK) primary care database in 2006 yielded similar results (71%, 37%, and 16%, respectively). 29 These treatment levels might appear suboptimal. However, the denominator includes every patient diagnosed with HF within a primary care population of 1.6 million people. It reflects the "real world" independently of factors characterizing entry into many cohorts: documentation or impairment of left ventricular function, 30 -32 recent hospitalization, 31, 33 and attending multidisciplinary or specialized services. 30, 32 Treatment levels in such cohorts are inevitably higher, promoted by specialist care or selected institutions.
Remarkably few international reports are representative of the general primary care population. [33] [34] [35] [36] [37] In similar time periods, ACEI/ARB and ␤-blocker use was comparable in the United States. 34, 35 Although ␤-blockade was apparently higher in the Netherlands (55%), 33 this registry examined patients discharged from hospital. Likewise, the high rates reported in 2 Swedish studies (64%-68%) 36 ,37 may reflect bias in selection of primary care centers. Nevertheless, ACEI/ARB and ␤-blocker rates in best-practice cohorts typically exceed 75%. 38 -40 Such high uptakes should be attainable in the wider population because contraindications to therapy are uncommon. Among 18 307 patients with HF enrolled in the US Get With the Guidelines program, only 13% had a contraindication to ACEI/ARB and 7% to ␤-blockers. 41 These suboptimal UK uptakes may reflect failings in health policy. Primary care performance is incentivized under the Quality and Outcomes Framework. However, ACEI/ARB and ␤-blocker targets were not set until 2006 and 2009, respectively. The impact of these changes merits future examination.
Optimal uptake of aldosterone antagonists is difficult to define. Unlike ACEI/ARB and ␤-blockers, which are indicated in all patients, spironolactone was until recently reserved only for those with severe symptoms. 42 However, since the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial in 2010, patients with milder symptoms are eligible for aldosterone antagonists. 43 The diffusion rate of this new evidence into practice also warrants monitoring.
Treatment: Socioeconomic Inequality
Only 4 studies have examined equality in prescribing of ACEIs or ␤-blockers. 2, 6, 7, 9 The US National Heart Failure Project constructed a nationally representative cohort of elderly Medicare beneficiaries by randomly sampling hospitalizations from each state between 1998 and 1999. 2 Adjusted likelihood of ACEI prescription at discharge was similar in patients of lower and higher socioeconomic status (RR, 1.03; 95% CI, 0.93-1.11). In contrast, the Dutch National Survey in General Practice from 2001 yielded mixed results. 9 No significant difference was observed between low and high socioeconomic class for ACEIs/ARBs (50% versus 53%), spironolactone (21% versus 21%), or digoxin (25% versus 23%). However, ␤-blocker prescribing was lower in patients of low socioeconomic class (31% versus 39%; PϽ0.05).
In the Scottish primary care continuous morbidity record between 1999 and 2000, prescribing of ACEIs, ␤-blockers, spironolactone, and digoxin did not vary by deprivation quintiles. 7 However, subsequent analysis of the UK DIN-LINK primary care database revealed significant inequalities in ␤-blocker prescribing. 6 This analysis used proprietary small area sociodemographic profiling based on 2001 census data. 44 Those living in areas of greatest deprivation were 16% less likely to receive ␤-blockers than those in the most affluent areas (adjusted odds ratio, 0.84; 95% CI, 0.71-0.98).
We have now clarified more recent circumstances in England using a nationally representative data set and validated index of multiple deprivation. Reassuringly, no socioeconomic gradients were observed for any therapy in men or women of any age. This is an important message for those contemplating reform in the United Kingdom, United States, and other countries. The fundamental goals of a health system are 3-fold: to ensure equity, effectiveness, and efficiency. 45 Improving health requires "leveling up," ie, increasing average levels while simultaneously reducing inequalities. 46 These principles underpin health policies throughout the world. An equally important message is the absence of similar evidence from other international healthcare systems. If inequalities are to be addressed, they must first be measured.
Strengths and Limitations
Our study uses the IMD 2007, which aggregates 38 indicators covering 7 dimensions of deprivation. The large nationally representative data source provides sufficient sample size to accurately stratify into socioeconomic quintiles. Area-based categorization of socioeconomic circumstances assumes homogeneity within a geographical area. Although individualand area-level measures make independent contributions to health outcomes, 47 composite measures correlate well with individual socioeconomic position and help to capture the contextual effects of living conditions. 48 Several important limitations also deserve mention. As with many epidemiological studies, case designation relies primarily on physician diagnosis rather than objective investigations. Changing incentives in primary care over time may influence reporting practices. 49 However, the working diagnosis is arguably the most relevant definition when examining prescribing behavior. The interest, particularly when studying inequality, is the recorded action directed toward patients who are believed to have a condition. We were also unable to examine or exclude inequalities in dosages of therapies.
Finally, about half of the patients have reduced and half have preserved ejection fraction, the latter proportion reportedly increasing over time. 50 Without objective ascertainment of left ventricular function, this relative ratio is uncertain. Changing diagnostic practices and the availability of openaccess echocardiography may also influence trends. The evidence supporting ACEIs/ARBs and ␤-blockers for HF with preserved ejection fraction is substantially weaker and does not mandate uniform treatment in international guidelines. [51] [52] [53] Nevertheless, these cornerstones of cardiovascular therapy are indicated in most patients for concurrent hyper-tension, coronary artery disease, angina, diabetes mellitus, and atrial fibrillation. Although uncertainty in the appropriateness of therapy must be acknowledged, patients with preserved ejection fraction should not simply be excluded in assessments of uptake. Moreover, the study time period was relatively short, and any increase in the population with preserved ejection fraction would actually lead to underestimation of the improvements in therapy for those with reduced ejection fraction.
Conclusions
HF incidence and prevalence continue to decrease year to year, paralleled by progressive improvements in the uptake of diseasemodifying therapies. Both medical therapy and outcomes for patients are equitable, regardless of socioeconomic status. This represents a clear success for the National Health Service. However, socioeconomic gradients in incidence and prevalence persist, treatment levels still fall short of exemplar European countries, and case fatality rates have not improved. Future strategies should therefore aim to further increase overall treatment levels, to eradicate remaining age and sex inequalities, and to address the wider determinants of HF.
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CLINICAL PERSPECTIVE
Although we appeared to be facing a heart failure epidemic before the millennium, recent reports suggest that the incidence and prevalence of heart failure are falling. The delivery of survival-enhancing therapies has simultaneously increased. However, the fundamental goal of health care is to improve not only effectiveness but also equity. The present study examined these trends according to socioeconomic status using nationally representative primary care data from England. Heart failure incidence and prevalence continued to decrease, paralleled by improvements in uptake of disease-modifying therapies. Although gradients were apparent, the frequency of heart failure declined more in the most deprived, and the absolute gap between the deprived and affluent was reduced. In just 8 years, angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker uptake increased from 46% to 64%, ␤-blocker uptake increased from 12% to 41%, and spironolactone uptake increased from 3% to 20%. Reassuringly, no socioeconomic gradients were observed for any therapy in men or women of any age. Moreover, outcomes for patients were also equitable regardless of socioeconomic status. These are important messages for policy makers and those contemplating reform of health systems: Leveling up is achievable, increasing average levels while simultaneously reducing inequalities. However, there is no room for complacency. Future strategies should aim to address the wider determinants of heart failure, to increase treatment levels further, and to eradicate remaining inequalities. Only then will the goals of universal health care truly be realized. Table 2 . Age and sex standardized incidence, prevalence and one year case fatality rates (%) for heart failure, stratified by socioeconomic status. 
